

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: July 17, 2008

(use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

<b>Application Number</b>	10/079,949
<b>Filing Date</b>	2/19/2002
<b>First Named Inventor</b>	Ebrahim ZANDI
<b>Art Unit</b>	1652
<b>Examiner Name</b>	Prouty, Rebecca E.
<b>Attorney Docket Number</b>	064189-0501

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document Serial Number-Kind Code <sup>2</sup> (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number-Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/RP/	C49	BOUWMEESTER et al. (2004) "A physical and functional map of the human TNF- $\alpha$ /NF- $\kappa$ B signal transduction pathway" <i>Nature Cell Biol.</i> 6(2):97-105	
/RP/	C50	CHEN et al. (1996) "Site-specific Phosphorylation of I $\kappa$ B $\alpha$ by a Novel Ubiquitination-Dependent Protein Kinase Activity" <i>Cell</i> 84:853-862	
/RP/	C51	DELHASE et al. (1999) "Positive and Negative Regulation of I $\kappa$ B Kinase Activity Through IKK $\beta$ Subunit Phosphorylation" <i>Science</i> 284:309-313	
/RP/	C52	KARIN and DELHASE (1998) "JNK or IKK, AP-1 or NF- $\kappa$ B, which are the targets for MEK Kinase 1 action?" <i>Proc. Natl. Acad. Sci. USA</i> 95:9067-9069	

Examiner Signature	/Rebecca Prouty/	Date Considered	10/03/2008
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov/mpep/201.04-3. Entitle each reference issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check in this box if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete If Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<b>Application Number</b>	10/079,949	
Date Submitted: July 17, 2008 <i>(use as many sheets as necessary)</i>			<b>Filing Date</b>	2/19/2002	
Sheet	2	of	<b>First Named Inventor</b>	Ebrahim ZANDI	
			<b>Art Unit</b>	1652	
			<b>Examiner Name</b>	Prouty, Rebecca E.	
			<b>Attorney Docket Number</b>	064189-0501	

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
	C53	MERCURIO et al. (1997) "IKK-1 and IKK-2: Cytokine-Activated I $\kappa$ B Kinases Essential for NF- $\kappa$ B Activation" <i>Science</i> 278:860-866	cited on IDS of	7/02		
/RP/	C54	MERCURIO et al. (1999) "I $\kappa$ B Kinase (IKK)-Associated Protein 1, a Common component of the Heterogeneous IKK Complex" <i>Mol. Cell. Biol.</i> 19(2):1526-1538				
/RP/	C55	MILLER and ZANDI (2001) "Complete Reconstitution of Human I $\kappa$ B Kinase (IKK) Complex in Yeast" <i>J. Biol. Chem.</i> 276(39):36320-36326				

Examiner Signature	/Rebecca Prouty/	Date Considered	10/03/2008
--------------------	------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 201.04. 3 Entitled to receive the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the indication of the kind of patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is mandatory to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.